| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York; 2 Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California; 3 Translational Oncology Laboratory, Barts and the London Queen Mary's School of Medicine and Dentistry, London, United Kingdom; 4 Department of Viruses, Hormones, and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; and 5 Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom
Requests for reprints: Richard A. DiCioccio, Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-8059; Fax: 716-845-1698. E-mail: richard.dicioccio{at}roswellpark.org
STK15 is a putative oncogene that codes for a centrosome-associated, serine/threonine kinase, the normal function of which is to ensure accurate segregation of chromosomes during mitosis. Amplification of STK15 has been reported in ovarian tumors, suggesting a role in ovarian cancer pathology. STK15 is polymorphic with two single nucleotide substitutions (449t/a and 527g/a) in evolutionarily conserved regions causing amino acid changes (F31I and V57I). Two other nucleotide substitutions (287c/g and 1891g/c) of unknown significance are in 5' and 3' untranslated regions (UTR), respectively. To learn more about the involvement of STK15 in ovarian cancer, we genotyped and haplotyped these polymorphisms in three population-based ovarian cancer case-control studies from the United Kingdom, United States, and Denmark with 1,821 combined cases and 2,467 combined controls and calculated risks for developing ovarian cancer. Genotypes of individual polymorphisms in control groups of the United Kingdom, United States, and Denmark conformed to Hardy-Weinberg equilibrium. In combined cases and combined controls, rare allele frequencies were 0.23 and 0.21 for I31, 0.16 and 0.17 for I57, 0.08 and 0.07 for 5' UTR g, and 0.25 and 0.24 for 3' UTR c, respectively. Using FF common homozygotes of F31I as comparator, there was increased ovarian cancer risk to FI heterozygotes (odds ratio, 1.18; 95% confidence interval, 1.01-1.36), II homozygotes (odds ratio, 1.25; 95% confidence interval, 0.89-1.75), and I31 allele carriers (odds ratio, 1.17; 95% confidence interval, 1.02-1.35) in the combined group data. For either V57I, 5' UTR C/G, or 3' UTR G/C, all genotypic ovarian cancer risks were essentially in unity relative to their respective common homozygotes, VV, cc, or gg. Haplotype analysis of combined group data revealed seven haplotypes with frequencies between 0.02 and 0.5, with c-F-V-g the most common. None of the haplotype-specific risks significantly differed from unity relative to c-F-V-g. These results suggest a model of dominant inheritance of ovarian cancer risk by the I31 allele of F31I and that the I31 allele may be a common ovarian cancer susceptibility allele of low penetrance.
This article has been cited by other articles:
|
|
 |
|
  E. Ogawa, K. Takenaka, H. Katakura, M. Adachi, Y. Otake, Y. Toda, H. Kotani, T. Manabe, H. Wada, and F. Tanaka Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC) Ann. Surg. Oncol., February 1, 2008; 15(2): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Landen Jr., Y. G. Lin, A. Immaneni, M. T. Deavers, W. M. Merritt, W. A. Spannuth, D. C. Bodurka, D. M. Gershenson, W. R. Brinkley, and A. K. Sood Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients Clin. Cancer Res., July 15, 2007; 13(14): 4098 - 4104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, D. Li, C. Wei, S. Sen, A. M. Killary, C. I. Amos, D. B. Evans, J. L. Abbruzzese, and M. L. Frazier Aurora-A and p16 Polymorphisms Contribute to an Earlier Age at Diagnosis of Pancreatic Cancer in Caucasians Clin. Cancer Res., May 15, 2007; 13(10): 3100 - 3104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Gayther, H. Song, S. J. Ramus, S. K. Kjaer, A. S. Whittemore, L. Quaye, J. Tyrer, D. Shadforth, E. Hogdall, C. Hogdall, et al. Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer Cancer Res., April 1, 2007; 67(7): 3027 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gu, Y. Gong, M. Huang, C. Lu, M. R. Spitz, and X. Wu Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians Carcinogenesis, February 1, 2007; 28(2): 350 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Briassouli, F. Chan, and S. Linardopoulos The N-terminal domain of the Aurora-A Phe-31 variant encodes an E3 ubiquitin ligase and mediates ubiquitination of I{kappa}B{alpha} Hum. Mol. Genet., November 15, 2006; 15(22): 3343 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S E Bojesen, S K Kjaer, E V S Hogdall, B L Thomsen, C K Hogdall, J Blaakaer, A Tybjaerg-Hansen, and B G Nordestgaard Increased risk of ovarian cancer in integrin {beta}3 Leu33Pro homozygotes Endocr. Relat. Cancer, December 1, 2005; 12(4): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lesueur, P. D. Pharoah, S. Laing, S. Ahmed, C. Jordan, P. L. Smith, R. Luben, N. J. Wareham, D. F. Easton, A. M. Dunning, et al. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer Hum. Mol. Genet., August 15, 2005; 14(16): 2349 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ewart-Toland, Q. Dai, Y.-T. Gao, H. Nagase, M. G. Dunlop, S. M. Farrington, R. A. Barnetson, H. Anton-Culver, D. Peel, A. Ziogas, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types Carcinogenesis, August 1, 2005; 26(8): 1368 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Kimura, T. Mori, J. Conroy, N. J. Nowak, S. Satomi, K. Tamai, and H. Nagase Two Functional Coding Single Nucleotide Polymorphisms in STK15 (Aurora-A) Coordinately Increase Esophageal Cancer Risk Cancer Res., May 1, 2005; 65(9): 3548 - 3554. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
